ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
ASCO 2024 preview – toxicity looms large for J&J
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
MacroGenics gets that sinking feeling
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
MacroGenics pays for its ASCO exuberance
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
